The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Worldwide burden of cancer attributable to HPV by site, country and HPV type
Open accessAbstract
HPV is the cause of almost all cervical cancer and is responsible for a substantial fraction of other anogenital cancers and oropharyngeal cancers. Understanding the HPV‐attributable cancer burden can boost programs of HPV vaccination and HPV‐based cervical screening. Attributable fractions (AFs) and the relative contributions of different HPV types were derived from published studies reporting on the prevalence of transforming HPV infection in cancer tissue. Maps of age‐standardized incidence rates of HPV‐attributable cancers by country from GLOBOCAN 2012 data are shown separately for the cervix, other anogenital tract and head and neck cancers. The relative contribution of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 was also estimated. 4.5% of all cancers worldwide (630,000 new cancer cases per year) are attributable to HPV: 8.6% in women and 0.8% in men. AF in women ranges from <3% in Australia/New Zealand and the USA to >20% in India and sub‐Saharan Africa. Cervix accounts for 83% of HPV‐attributable cancer, two‐thirds of which occur in less developed countries. Other HPV‐attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000 anus (half occurring in men) and 13,000 penis. In the head and neck, HPV‐attributable cancers represent 38,000 cases of which 21,000 are oropharyngeal cancers occurring in more developed countries. The relative contributions of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 are 73% and 90%, respectively. Universal access to vaccination is the key to avoiding most cases of HPV‐attributable cancer. The preponderant burden of HPV16/18 and the possibility of cross‐protection emphasize the importance of the introduction of more affordable vaccines in less developed countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
HPV-associated head and neck cancer: a virus-related cancer epidemic
Marur, S., D'Souza, G., Westra, W. H., & Forastiere, A. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70017-6 · Cited by 1,816
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30143-7 · Cited by 1,635
Self-citationIntegrated genomic and molecular characterization of cervical cancer
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature21386 · Cited by 1,479
United Nations Development Program
(2006) · Encyclopedia of World Poverty · doi:10.4135/9781412939607.n718 · Cited by 1,301
Human papillomavirus and cervical cancer
Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60022-7 · Cited by 1,171
Self-citationGuan, P., Howell‐Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., & Clifford, G. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27485 · Cited by 927
Self-citationBruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F. X., de Sanjosé, S., & Castellsagué, X. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30099-7 · Cited by 824
HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
Castellsagué, X., Alemany, L., Quer, M., Halec, G., Quirós, B., Tous, S., Clavero, O., Alòs, L., Biegner, T., Szafarowski, T., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv403 · Cited by 740
Cited by
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Cell cycle regulation: p53-p21-RB signaling
Engeland, K. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00988-z · Cited by 1,274
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070
Soerjomataram, I., & Bray, F. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00514-z · Cited by 1,012
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Lechner, M., Liu, J., Masterson, L., & Fenton, T. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00603-7 · Cited by 979
The Role of Zinc in Antiviral Immunity
Read, S. A., Obeid, S., Ahlenstiel, C., & Ahlenstiel, G. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz013 · Cited by 749
Kombe Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G.-A., Zhou, Y., & Jin, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2020.552028 · Cited by 646
Epidemiology and burden of HPV-related disease
Serrano, B., Brotons, M., Bosch, F. X., & Bruni, L. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.006 · Cited by 560
Viral hijacking of cellular metabolism
Thaker, S. K., Ch’ng, J., & Christofk, H. R. (2019) · BMC Biology · doi:10.1186/s12915-019-0678-9 · Cited by 526
Lin, C., Franceschi, S., & Clifford, G. M. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30653-9 · Cited by 472
Self-citationThe HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets
Hoppe-Seyler, K., Bossler, F., Braun, J. A., Herrmann, A. L., & Hoppe-Seyler, F. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2017.07.007 · Cited by 457
Human papillomavirus-related oropharyngeal cancer
Taberna, M., Mena, M., Pavón, M. A., Alemany, L., Gillison, M. L., & Mesía, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx304 · Cited by 399
Hu, L., Bell, D., Antani, S., Xue, Z., Yu, K., Horning, M. P., Gachuhi, N., Wilson, B., Jaiswal, M. S., Befano, B., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy225 · Cited by 387
Cervical Cancer: An Overview of Pathophysiology and Management
Johnson, C. A., James, D., Marzan, A., & Armaos, M. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.02.003 · Cited by 382
Human papillomaviruses: diversity, infection and host interactions
McBride, A. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00617-5 · Cited by 369
Human Papillomavirus Vaccines: An Updated Review
Cheng, L., Wang, Y., & Du, J. (2020) · Vaccines · doi:10.3390/vaccines8030391 · Cited by 329
Cancers in Vietnam—Burden and Control Efforts: A Narrative Scoping Review
Pham, T., Bui, L., Kim, G., Hoang, D., Tran, T., & Hoang, M. (2019) · Cancer Control · doi:10.1177/1073274819863802 · Cited by 313
Stevanović, S., Helman, S. R., Wunderlich, J. R., Langhan, M. M., Doran, S. L., Kwong, M. L. M., Somerville, R. P. T., Klebanoff, C. A., Kammula, U. S., Sherry, R. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2722 · Cited by 307
Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer
Kjaer, S. K., Dehlendorff, C., Belmonte, F., & Baandrup, L. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab080 · Cited by 304
Olesen, T. B., Sand, F. L., Rasmussen, C. L., Albieri, V., Toft, B. G., Norrild, B., Munk, C., & Kjær, S. K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30682-x · Cited by 289
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
Basukala, O., & Banks, L. (2021) · Viruses · doi:10.3390/v13101892 · Cited by 137
Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
Sankaranarayanan, R., Basu, P., Kaur, P., Bhaskar, R., Singh, G. B., Denzongpa, P., Grover, R. K., Sebastian, P., Saikia, T., Oswal, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30531-5 · Cited by 136
HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers
Ren, S., Gaykalova, D. A., Guo, T., Favorov, A. V., Fertig, E. J., Tamayo, P., Callejas-Valera, J. L., Allevato, M., Gilardi, M., Santos, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01431-8 · Cited by 93
Canfell, K., Kim, J. J., Kulasingam, S., Berkhof, J., Barnabas, R., Bogaards, J. A., Campos, N., Jennett, C., Sharma, M., Simms, K. T., et al. (2019) · Papillomavirus Research · doi:10.1016/j.pvr.2019.100184 · Cited by 68
Ouh, Y.-T., Min, K.-J., Cho, H. W., Ki, M., Oh, J.-K., Shin, S. Y., Hong, J. H., & Lee, J.-K. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e14 · Cited by 51
Hatterschide, J., Brantly, A. C., Grace, M., Munger, K., & White, E. A. (2020) · Journal of Virology · doi:10.1128/jvi.01024-20 · Cited by 33
Xu, M., Choi, J., Capasso, A., & DiClemente, R. (2024) · Adolescent Health, Medicine and Therapeutics · doi:10.2147/ahmt.s394119 · Cited by 30
Mafi, S., Theuillon, F., Meyer, S., Woillard, J.-B., Dupont, M., Rogez, S., Alain, S., & Hantz, S. (2025) · PLOS ONE · doi:10.1371/journal.pone.0320978 · Cited by 10
“HPV16 and 18 are responsible for at least 70% of cervical cancers [5,6].”
Metadata
- Authors
- de Martel, C., Plummer, M., Vignat, J., & Franceschi, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2017-06-08
- Volume
- 141
- Issue
- 4
- Pages
- 664-670
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2605365014
- Cited by
- 2,322
- References
- 26
- FWCI
- 104.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.